Early intradetrusor injection of Onabotulinumtoxin A in patients with subacute spinal cord injury: The SCIBOT study
Scandinavian Journal of Urology · 07.07.2026 · 61 · 188-194
DOI: 10.2340/sju.v61.46428 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Scandinavian Journal of Urology, online erschienen am 07.07.2026. Verfasst von Ole Jacob Nilsen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.…. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Spinal Cord Injuries, Urinary Bladder, Overactive, Urinary Bladder, Neurogenic. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
The aim of this study was to examine if early intradetrusor injections of onabotulinumtoxin A (BTX) permanently prevent the development of neurogenic detrusor overactivity (NDO) in patients with spinal cord injury (SCI). Materials and methods: Double-blinded randomised controlled trial. Patients with a sensorimotor complete subacute traumatic suprasacral SCI received intradetrusor injection of BTX or placebo at baseline (within 12 weeks after injury) and 3 months later. Urodynamic and clinical evaluation was performed at baseline, at 3 months, at 12 months and at long-term follow-up after >24 months. The primary endpoint was occurrence of NDO with contractions above 40 cmH2O. The secondary endpoints included comparisons of urodynamic parameters, as well as clean intermittent catheterisation (CIC) frequency, occurrence of urinary incontinence, and quality of life (QOL) evaluated by questionnaires.
Results
Nine patients were included, with four in the placebo group and five patients in the BTX group. Two patients in the placebo group but none in the BTX group developed NDO with contractions above 40 cmH2O. Regarding the secondary outcome variables, there were lower maximum detrusor pressure, less frequent CIC, less incontinence, and better QOL in the BTX group at >24 months follow up. Although there was a trend toward better outcome measures, none of the differences were statistically significant. No adverse events were related to BTX in either group.
Conclusion
Intradetrusor injection of BTX in patients with SCI during the subacute phase seems to be safe and may be beneficial, but further studies are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. ojnilsen@ous-hf.no.
- Sunnaas Rehabilitation Hospital, Spinal Unit, Nesodden, Norway.
- Department of Urology, Oslo University Hospital, Oslo, Norway.
- Department of Biomedicine, Experimental Biology Unit, Faculty of Medicine of the University of Porto, Porto, Portugal.
- Section of Reconstructive and Oncologic Plastic Surgery, Department of Cancer Surgery, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
ORCID-Profile: Ole Jacob Nilsen, Thomas Glott, Henriette Veiby Holm, Célia Duarte Cruz, Lars Frich
Zitieren
APA
Nilsen, O. J., Glott, T., Veiby Holm, H., Cruz, C. D., & Frich, L. (2026). Early intradetrusor injection of Onabotulinumtoxin A in patients with subacute spinal cord injury: The SCIBOT study. Scandinavian Journal of Urology, 61, 188-194. https://doi.org/10.2340/sju.v61.46428
Vancouver
Nilsen OJ, Glott T, Veiby Holm H, Cruz CD, Frich L. Early intradetrusor injection of Onabotulinumtoxin A in patients with subacute spinal cord injury: The SCIBOT study. Scandinavian Journal of Urology. 2026;61:188-194. doi:10.2340/sju.v61.46428
BibTeX
@article{Nilsen2026,
author = {Nilsen, Ole Jacob and Glott, Thomas and Veiby Holm, Henriette and Cruz, Célia Duarte and Frich, Lars},
title = {Early intradetrusor injection of Onabotulinumtoxin A in patients with subacute spinal cord injury: The SCIBOT study},
journal = {Scandinavian Journal of Urology},
year = {2026},
volume = {61},
pages = {188--194},
doi = {10.2340/sju.v61.46428}
}
EUVIMED